Playlist

Production Surge: Babadayhan Textile Complex Generates Over 140 Million Manats in Output

30 Jul. 13:53

Source

During the first six months of 2026, the Babadayhan Textile Complex manufactured products totaling more than 140 million 858 thousand manats. This performance reflects a growth rate of over 130.1 percent compared to the corresponding period of the previous year, as reported by the Turkmenistan newspaper.

The state-of-the-art facility maintains a substantial annual processing capacity, capable of yielding 3,300 metric tons of high-grade yarn, 20 million square meters of diverse fabrics—including dyeing capabilities for 18 million square meters—and 3.5 million finished garments. Products from this enterprise continue to experience high market demand.

Specific grades of cotton yarn, including counts 31/1, 51/1, and 68/1, as well as fine combed yarn count 85/1, remain in strong demand. Manufactured through the processing of domestic cotton, these products meet global standards and represent key export-oriented commodities for the nation.

Since the beginning of the year, finished garments under the "Mäne" brand, designed to meet rigorous ecological requirements, have been distributed to consumers in scheduled batches. A significant volume of these items is made available through specialized retail outlets managed by the Ministry of Textile Industry.

‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌

Simple Vitamin Shows Surprising Results in Pre-Cancerous Blood Conditions, Study Finds

Today in 02:02

Source

Daily high-dose supplementation of vitamin C can significantly reduce mortality risks and help prevent severe medical complications in patients with pre-cancerous blood conditions. Researchers from the Van Andel Institute in the United States and Copenhagen University Hospital in Denmark reached this conclusion following a comprehensive three-year follow-up study. The international "EVITA" trial involved volunteers who were administered 1,000 mg of vitamin C daily over the course of a year, while a control group received a placebo.

Although initial hypotheses suggested vitamin C might directly inhibit abnormal cell proliferation, researchers found its primary benefit lay in strengthening the body, reducing systemic inflammation, and lowering rates of anemia, pneumonia, and internal bleeding. Over the three-year observation period, the vitamin C group exhibited a significantly higher survival rate compared to the placebo group. While experts emphasize that these findings remain preliminary and require larger clinical trials before reshaping formal medical treatment protocols, vitamin C continues to show promising potential in supportive patient care.

‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌